Roche's Actemra improves juvenile arthritis symptoms in Phase III
This article was originally published in Scrip
Roche has released top-line data from a Phase III study of its first-in-class interleukin-6 (IL-6) inhibitor Actemra (tocilizumab) that shows it improves the signs and symptoms of systemic onset juvenile idiopathic arthritis (sJIA) compared with placebo. The company plans to submit data from this trial – known as TENDER – for presentation at an upcoming scientific meeting. Full data and a safety follow-up will used to support global regulatory filings for a sJIA indication.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.